Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie - Lorenzen, Sylvie; Haag, Georg Martin; Eisenmenger, Andreas; Karapanagiotou-Schenkel, Irini; Lordick, Florian (European journal of cancer, 2015)
Gesehen am 27.09.2016